UCB Gelecekteki Büyüme
Future kriter kontrolleri 3/6
UCB kazanç ve gelirin sırasıyla yıllık 17.3% ve 9.7% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 17.6% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 19.3% olacağı tahmin edilmektedir.
Anahtar bilgiler
17.3%
Kazanç büyüme oranı
17.61%
EPS büyüme oranı
| Pharmaceuticals kazanç büyümesi | 10.7% |
| Gelir büyüme oranı | 9.7% |
| Gelecekteki özkaynak getirisi | 19.34% |
| Analist kapsamı | Good |
| Son güncelleme | 08 May 2026 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Analiz Güncellemesi • Apr 30
UCB: Epilepsy Portfolio Execution To Drive Future Earnings Power Upside
The analyst fair value estimate for UCB has shifted from €310 to €340, reflecting updated assumptions on revenue growth, higher projected profit margins, a slightly adjusted discount rate, a revised future P/E, and recent Street research in which analysts highlight UCB's epilepsy portfolio and reset price targets in the €300 to €340 range. Analyst Commentary Recent Street research on UCB has been mixed, with some caution on near-term risk and reward but also clear pockets of optimism tied to its neuroscience and epilepsy franchises.
Analiz Güncellemesi • Apr 16
UCB: Epilepsy And Neuroscience Execution Will Shape Balanced Risk Reward Profile
Analysts have adjusted the UCB price target toward €285, reflecting a blend of more cautious views that see risk and reward as balanced around €260 and more optimistic calls pointing toward €304 to €340, supported by expectations for its epilepsy portfolio and broader neuroscience exposure. Analyst Commentary Bullish Takeaways Bullish analysts see upside toward €304 to €340, suggesting that current pricing does not fully reflect expectations around the epilepsy portfolio and broader neuroscience pipeline.Analiz Güncellemesi • Apr 01
UCB: Epilepsy Franchise And Dermatology Data Will Shape Future Risk Reward Balance
Narrative Update on UCB The analyst price target for UCB has been adjusted slightly lower to about €285. This reflects a blend of more cautious views that see a balanced risk and reward at current levels, and more optimistic targets that highlight UCB's epilepsy portfolio and recent upward revisions from several banks.Analiz Güncellemesi • Mar 18
UCB: Epilepsy And Psoriatic Arthritis Execution Will Shape Future Risk Reward Balance
The updated analyst price target for UCB moves to €284.85 from €275.74. This reflects a mix of more conservative revenue growth assumptions, higher expected profit margins, and a lower future P/E multiple, in line with recent research that balances enthusiasm around epilepsy assets with a more measured view on risk and reward.
Analiz Güncellemesi • Mar 04
UCB: Epilepsy Franchise Expectations Will Eventually Strain Current Share Price
We are lifting our fair value estimate for UCB from €173.07 to €209.22, reflecting higher assumed revenue growth and profit margins as analysts highlight a stronger outlook for the epilepsy franchise and raise price targets into the €300+ range. Analyst Commentary Recent Street research on UCB has centered on the epilepsy franchise and the broader neuroscience portfolio, with several firms updating their views and price targets.Analiz Güncellemesi • Feb 18
UCB: Epilepsy Pipeline Progress And Execution Will Shape Future Upside Balance
Our Analyst Price Target for UCB has moved higher from €261.42 to €275.74, reflecting analysts' updated assumptions on revenue growth, profitability and P/E in light of recent Street target lifts to around €304 to €310. Analyst Commentary Recent Street research on UCB has centered on higher price targets, with bullish analysts adjusting their views to reflect updated assumptions on revenue, profitability and P/E.Analiz Güncellemesi • Feb 04
UCB: Future Earnings Power To Reflect Rare Disease And Epilepsy Execution
Analysts have raised their price target on UCB to €310 from €270, citing updated assumptions for revenue growth, profit margins and a slightly lower future P/E multiple as the main drivers of the change. Analyst Commentary Recent commentary from bullish analysts has centered on higher valuation support for UCB, with the new €310 price target used as a reference point for what they see as stronger execution and earnings potential than previously modeled.Analiz Güncellemesi • Jan 21
UCB: Late-Stage Pipeline And Margin Execution Will Shape Balanced Upside Potential
Analysts raised their price target on UCB to €310 from €270, citing updated expectations for slightly stronger revenue growth, improved profit margins, and a modestly lower future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher €310 target as a sign that they see current valuation as not fully reflecting updated revenue and margin expectations.Analiz Güncellemesi • Jan 07
UCB: Raising Future Fair Value On Strengthening Rare Disease And Epilepsy Franchise
Analysts have raised their fair value estimate for UCB from €255 to €310, citing recent price target increases from the Street and updated assumptions on revenue growth, profit margins and future P/E levels. Analyst Commentary Bullish analysts have recently adjusted their views on UCB, with fresh price targets that now cluster around €290 to €310.Analiz Güncellemesi • Dec 18
UCB: Expanding Late-Stage Pipeline And New Launches Will Drive Future Upside
UCB's analyst price target has been raised from EUR 258.33 to EUR 264.67 as analysts factor in slightly stronger revenue growth expectations, despite a modestly lower projected profit margin and only a small uptick in future valuation multiples. Analyst Commentary Recent price target increases signal that bullish analysts see a more attractive risk reward profile for UCB, driven by improving growth visibility and confidence in execution.Analiz Güncellemesi • Dec 04
UCB: Pipeline Execution And New Launches Will Support Balanced Future Upside Potential
UCB's fair value estimate has been nudged higher to approximately EUR 258 from EUR 257, reflecting analysts' upward revisions to price targets, with recent moves to EUR 240, EUR 285 and EUR 290. These changes highlight confidence in the company's earnings trajectory despite slightly softer margin and growth assumptions.Analiz Güncellemesi • Nov 20
UCB: Recent Pipeline Advances And Margin Strength Will Drive Share Price Higher
Analysts have slightly raised their fair value estimate for UCB to €256.67. They cite recent upward revisions to price targets, supported by continued expectations for stable profit margins and healthy revenue growth.Analiz Makalesi • Nov 11
UCB (EBR:UCB) Could Easily Take On More Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analiz Güncellemesi • Nov 06
UCB: Strong Profit Margins And Momentum Will Drive Shares Higher
UCB's fair value estimate has increased by approximately EUR 4.50, as analysts highlight robust performance and upward revisions to price targets. This follows renewed confidence in the company’s profit margin outlook.Analiz Güncellemesi • Oct 22
Analysts Raise UCB Price Targets Amid Positive Sector Outlook and Improved Growth Forecasts
UCB's analyst price target has been raised from €240.28 to €251.11, as analysts cite upward revisions to revenue growth forecasts along with an improved sector outlook. Analyst Commentary Recent analyst actions reflect a strongly positive sentiment toward UCB's outlook, as multiple firms have revised their price targets upward and maintained favorable ratings.Analiz Makalesi • Oct 14
Market Participants Recognise UCB SA's (EBR:UCB) Earnings Pushing Shares 25% Higher
UCB SA ( EBR:UCB ) shares have continued their recent momentum with a 25% gain in the last month alone. Looking back a...Analiz Güncellemesi • Oct 08
Aging Populations And Emerging Markets Will Unlock Opportunity
UCB's analyst price target has been increased from €229.06 to €240.28. This change reflects improved revenue growth expectations and profit margins highlighted by recent analyst updates.Analiz Güncellemesi • Sep 24
Aging Populations And Emerging Markets Will Unlock Opportunity
The slight increase in UCB’s consensus price target to €229.06 reflects improved revenue growth forecasts, while profit margin expectations remain stable. What's in the News Three-year data from BE HEARD trials show sustained efficacy and quality of life improvements with BIMZELX® in moderate-to-severe hidradenitis suppurativa, with better outcomes linked to earlier treatment.Analiz Güncellemesi • Aug 27
Aging Populations And Emerging Markets Will Unlock Opportunity
Analysts have raised their price target for UCB to €223.17, citing robust fundamentals, resilient earnings growth, and improved confidence in management despite recent share price weakness. Analyst Commentary Recent share price pullback seen as disconnected from underlying business strength.Analiz Makalesi • Jul 17
UCB SA (EBR:UCB) Not Lagging Market On Growth Or Pricing
When close to half the companies in Belgium have price-to-earnings ratios (or "P/E's") below 14x, you may consider UCB...
Yeni Analiz • Mar 02
BIMZELX's Successful Launch Will Expand Future Market Opportunities In Dermatology And Rheumatology
UCB's new product launches and high R&D success rate are driving anticipated revenue and margin growth across global markets.Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2028 | 10,669 | 2,827 | 3,152 | 3,685 | 16 |
| 12/31/2027 | 9,531 | 2,264 | 2,562 | 3,025 | 17 |
| 12/31/2026 | 8,457 | 1,762 | 1,943 | 2,400 | 17 |
| 12/31/2025 | 7,741 | 1,558 | 1,842 | 2,291 | N/A |
| 9/30/2025 | 7,295 | 1,445 | 1,514 | 1,934 | N/A |
| 6/30/2025 | 6,848 | 1,332 | 1,185 | 1,576 | N/A |
| 3/31/2025 | 6,500 | 1,199 | 1,053 | 1,409 | N/A |
| 12/31/2024 | 6,152 | 1,065 | 920 | 1,242 | N/A |
| 9/30/2024 | 5,803 | 653 | 745 | 1,066 | N/A |
| 6/30/2024 | 5,454 | 240 | 569 | 889 | N/A |
| 3/31/2024 | 5,318 | 292 | 507 | 825 | N/A |
| 12/31/2023 | 5,182 | 343 | 445 | 761 | N/A |
| 6/30/2023 | 5,111 | 332 | 620 | 975 | N/A |
| 3/31/2023 | 5,279 | 376 | 684 | 1,047 | N/A |
| 12/31/2022 | 5,447 | 420 | 748 | 1,119 | N/A |
| 6/30/2022 | 5,854 | 887 | 982 | 1,462 | N/A |
| 3/31/2022 | 5,816 | 971 | 1,021 | 1,508 | N/A |
| 12/31/2021 | 5,777 | 1,055 | 1,060 | 1,553 | N/A |
| 9/30/2021 | 5,647 | 996 | 907 | 1,371 | N/A |
| 6/30/2021 | 5,517 | 936 | 754 | 1,188 | N/A |
| 3/31/2021 | 5,432 | 834 | 743 | 1,135 | N/A |
| 12/31/2020 | 5,347 | 732 | 732 | 1,081 | N/A |
| 6/30/2020 | 5,198 | 743 | 706 | 908 | N/A |
| 3/31/2020 | 5,056 | 767 | 647 | 895 | N/A |
| 12/31/2019 | 4,913 | 790 | 588 | 882 | N/A |
| 6/30/2019 | 4,686 | 652 | N/A | 950 | N/A |
| 3/31/2019 | 4,659 | 722 | N/A | 1,020 | N/A |
| 12/31/2018 | 4,632 | 792 | N/A | 1,089 | N/A |
| 6/30/2018 | 4,569 | 872 | N/A | 1,092 | N/A |
| 3/31/2018 | 4,522 | 812 | N/A | 1,010 | N/A |
| 12/31/2017 | 4,474 | 752 | N/A | 927 | N/A |
| 9/30/2017 | 4,400 | 708 | N/A | N/A | N/A |
| 6/30/2017 | 4,325 | 664 | N/A | 780 | N/A |
| 3/31/2017 | 4,236 | 604 | N/A | 604 | N/A |
| 12/31/2016 | 4,147 | 543 | N/A | 427 | N/A |
| 9/30/2016 | 4,051 | 439 | N/A | N/A | N/A |
| 6/30/2016 | 3,955 | 334 | N/A | 66 | N/A |
| 3/31/2016 | 3,916 | 299 | N/A | 156 | N/A |
| 12/31/2015 | 3,876 | 264 | N/A | 246 | N/A |
| 9/30/2015 | 3,773 | 266 | N/A | 388 | N/A |
| 6/30/2015 | 3,670 | 268 | N/A | 530 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: UCB 'nin tahmini kazanç büyümesi (yıllık 17.3% ) tasarruf oranının ( 2.4% ) üzerindedir.
Kazançlar ve Piyasa: UCB şirketinin kazançlarının (yıllık 17.3% ) Belgian pazarından (yıllık 13.9% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Kazançları: UCB şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.
Gelir ve Pazar: UCB şirketinin gelirinin (yıllık 9.7% ) Belgian pazarından (yıllık 6.9% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Geliri: UCB şirketinin gelirinin (yıllık 9.7% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: UCB 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 19.3 %).
Büyüyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/11 05:30 |
| Gün Sonu Hisse Fiyatı | 2026/05/11 00:00 |
| Kazançlar | 2025/12/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
UCB SA 40 Bu analistlerden 17, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Charles Pitman | Barclays |
| Brian Bourdot | Barclays |
| Charles Pitman | Barclays |